Navigation Links
Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/10/2013

ly significant difference between treatment outcomes of the vaccinated and non-vaccinated groups.

Based on the success of preclinical studies, the PATH Malaria Vaccine Initiative (MVI) and Inovio announced a follow-on collaboration to advance Inovio's malaria DNA vaccine and electroporation technology into a phase I/IIa clinical trial in 2014. Established at PATH through an initial grant from the Bill & Melinda Gates Foundation, MVI's mission is to accelerate the development of malaria vaccines and ensure their availability and accessibility in the developing world. 

Corporate DevelopmentInovio continues to advance discussions with large pharmaceutical companies with the goal of securing strategic partnerships to advance the development of SynCon® vaccines.

Subsequent to the quarter, Inovio and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) received a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of Inovio's next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation.

Inovio was recognized with Vaccine Industry Excellence (ViE) Awards for "Best Therapeutic Vaccine" and "Best Early Stage Biotech" at the World Vaccine Congress. The ViE Awards recognize outstanding vaccine advancements and achievements of vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders.

About Inovio Pharmaceuticals, Inc. Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown i
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
6. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Miles Holder, formerly of Micron Research and ... team as Sales/Marketing Manager. Mr. Holder has over 25 ... the graphite industry. , “We are thrilled to be ... Trinkley, VP of Market and Product Development for Graphel ... the graphite industry, along with his proven track record ...
(Date:11/26/2014)... DE (PRWEB) November 26, 2014 ... Heroes recognition reception on December 5, 2014, in San ... meeting. The MPN Heroes event will honor clinicians, caregivers, ... field of myeloproliferative neoplasms (MPNs). , Special guest ... discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... 25 novembre 2014 Theravalues Corporation est fier ... marché européen au salon Hi Europe 2014 (du ... ). Curcumine la plus biodisponible actuellement ... (non-cristalline) à des ingrédients approuvés par les règlements ... jaune présent dans la racine de curcuma ( ...
(Date:11/26/2014)... /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il lancio ... di Hi Europe 2014 (dal 2 al 4 dicembre, ... della curcumina con la maggiore biodisponibilità di sempre, con ... approvati dalle norme europee. La curcumina è ... ( Curcuma longa ) che è stata associata con ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... Mass., Sept. 6 Boston Scientific,Corporation (NYSE: BSX ... elected Ray Elliott as a Director. Mr. Elliott, ... Inc.,Previously, he served as Chairman, President and Chief Executive ... Zimmer since 1997. Mr. Elliott,has extensive operating and director ...
... Proteon Therapeutics,( http://www.proteontherapeutics.com ), a privately held ... the,medical needs of patients with renal and ... with its current investor syndicate.,Proteon will use ... candidate,PRT-201, into human clinical studies in both ...
... a world leader in,radiation oncology and non-invasive ... radiotherapy, stereotactic radiosurgery and clinical,workflow solutions at ... 2007 meeting in Barcelona, Spain, September 8-13. ... health care,professionals are expected at the Ninth ...
Cached Biology Technology:Boston Scientific Announces Election of Ray Elliott to Its Board of Directors 2Boston Scientific Announces Election of Ray Elliott to Its Board of Directors 3Proteon Therapeutics Completes $12 Million Financing and Hires CFO 2Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability 2Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability 3
(Date:11/4/2014)... (Philadelphia, PA) – Temple University School of Medicine ... Explorations winner, an initiative funded by the Bill ... MPH, Professor of Obstetrics, Gynecology and Reproductive Sciences; ... at Temple University School of Medicine will pursue ... titled "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", ...
(Date:11/4/2014)... of Madagascar,s 101 species of lemurs are threatened with ... rainforests they call home. A new study by Rice ... on rainforest tree populations, which raises concerns about the ... rich biodiversity. , A large proportion of trees in ... in turn disperse the seeds of their fruit trees ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® , ... life sciences company focused on commercialization of its ... for the treatment of neurological and neuropsychiatric disorders, ... Property has issued a Notice of Allowance for ... is co-owned by NeuroSigma and the Regents of ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... took a global corps of scientists approximately $500 million and ... the human genome. Five years later, Boston College Biologist Gabor ... analyze half a million DNA sequences in 10 minutes. ... new breed of computer programs able to accurately process the ...
... New Rochelle, NY, March 27, 2008 -Sustaining hope in ... amyotrophic lateral sclerosis (ALS) should be a goal of ... continuum from focusing on the self to concern for ... April issue (Volume 8, Number 3) of Journal of ...
... patient lying on an operating table, while another student conducts ... a real OR or treatment room, except that the patients ... theyre robots., These high-tech, electronically outfitted mannequins are equipment in ... at the Johns Hopkins Outpatient Center in East Baltimore that ...
Cached Biology News:Software developed by Boston College lab delivers speed and accuracy to genome research 2Software developed by Boston College lab delivers speed and accuracy to genome research 3Hope among patients with ALS may take a variety of forms 2Actor-robots 'staff' part of new $5M simulation training center 2
... Wellpro 384, compatible ... automated liquid handling system ... quickly and accurately prepares ... dilutions. The Wellpro ...
...
...
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
Biology Products: